New Guidance on Latest Treatments for Early Alzheimer’s Disease

| September 11, 2023

New therapies for early Alzheimer’s disease are changing how patients are being managed. Monoclonal antibodies that remove amyloid-β plaques in the brain are bringing new hope to people whose lives have been affected by Alzheimer’s disease. Now, the American Academy of Neurology (AAN) has developed new guidelines for patients. The guidelines are derived from expert consensus about new and emerging therapies.

“Neurologists care for millions of people with Alzheimer’s disease and many people with early forms of dementia are eager to learn if these new therapies could help them,” said AAN president Dr. Carlayne E. Jackson. “To help neurologists provide the highest quality care, experts with the American Academy of Neurology have summarized the available evidence on anti-amyloid monoclonal antibodies so that neurologists, patients and their caregivers can make informed decisions together about possible treatment with these therapies.”

The guidelines provide the latest available information on lecanemab, aducanumab and donanemab. “Recent data on lecanemab and other monoclonal antibody infusions targeting amyloid-β protein make clear that new agents are highly likely to be part of the toolkit for neurologists caring for people with Alzheimer’s disease,” said Dr. Vijay K. Ramanan with the Mayo Clinic in Rochester, Minnesota.

Lecanemab received traditional FDA approval on July 6, 2023. Aducanumab received accelerated approval from the FDA in June 2021, but has not yet received traditional approval. Aducanumab is available only to individuals participating in a clinical trial. Donanemab is not yet approved, but a decision on traditional FDA approval is expected within the next 4 months. All of these agents are administered through regular infusions and monitoring with multiple brain scans.

Currently, only individuals with early symptomatic forms of the disease, mild cognitive impairment or mild dementia due to Alzheimer’s disease, may qualify to receive lecanemab. There is a concern that some patients may take these drugs inappropriately out of desperation. Neurologists says all older adults should be counseled about certain genetic risk factors and must not have a history of strokes.

If a person is taking certain anticoagulant medications that are commonly prescribed to older adults, they may not be eligible. The goal of using these therapies is to remove amyloid-β plaques and slow cognitive decline.

While these new therapies are not a cure for the disease, there is reason for optimism as there are dozens of very promising new agents in the development stage.

John Schieszer is an award-winning national journalist and radio and podcast broadcaster of The Medical Minute. He can be reached at medicalminutes@gmail.com.

Share this story!
Coffee and Tea Drinking Associated with Significant Health Benefits
Drinking coffee and tea on a regular basis may be protective against dementia as well as some types of cancer...
AI-Powered Chatbots Changing Medicine
AI is helping people to quit smoking, improving diagnostics, preventative medicine, medical records and other healthcare practices...

Related

Pregnant at 50: The menopause baby
There could be greater risks in mid-life pregancies, but technology has made it easier. Women over 50 are deciding to have babies....
Top warning signs you may be having a heart attack
Read the most common warning signs of a heart attack so that you can get necessary medical attention when it’s needed....
How to Find a Cheaper Medicare Prescription Drug Plan
"My Part D premium is increasing again in 2025, so I would like to use the fall open enrollment to find and sign up for...
Hospital stays: How to keep your mind and body active during your visit
Keeping mind and body active while hospitalized is easier than you think -- Even if you are confined to bed full-time!...
How to Ease the Winter Blues
"What can you tell me about seasonal affective disorder?"...
Should you go under the knife for stents with Angina?
Some surgeries save lives, but there are procedures worth questioning....

BE IN THE KNOW

NWPT-Subscribe

Recent Posts

Betty Jenkins & StoryCorps
Dealing with Social Security Issues: A Personal Story
Still Time for Sunflowers
Always Room for Tomatoes
Differences Between Annual Exam and ‘Welcome to Medicare’ Exam

BE IN THE KNOW

NWPT-Subscribe

Recent Posts

Betty Jenkins & StoryCorps
Dealing with Social Security Issues: A Personal Story
Still Time for Sunflowers
Always Room for Tomatoes
Differences Between Annual Exam and ‘Welcome to Medicare’ Exam